Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Servier Continues Oncology Winning Streak With Tibsovo Approval For MDS

Oct 25 2023

• By Alaric DeArment

The FDA approved Servier's Tibsovo for IDH1-mutated relapsed/refractory myelodysplastic syndrome • Source: Shutterstock

Related Content

ASCO 2023 - Servier’s Vorasidenib Puts The Brakes On Brain Cancer In INDIGO

Jun 04 2023

Rigel Ready To Hit The Ground Running After Early AML Drug Approval

Dec 02 2022

Tibsovo Approval Is A Stepping Stone For Servier’s Longer-Term Oncology Strategy

Aug 26 2021

Tibsovo Gets A Win In AML Following Servier Takeover

Aug 03 2021

Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases

Dec 22 2020

Related Companies

Bristol Myers Squibb Company

Otsuka Pharmaceutical Co. Ltd.

Agios Pharmaceuticals, Inc.

Rigel Pharmaceuticals, Inc.

Additional Topics

Approvals Business Strategies Commercial Cancer BioPharmaceutical

More from New Products

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window